



(43) International Publication Date
29 December 2016 (29.12.2016)

(10) International Publication Number
WO 2016/209707 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) *C07K 14/00* (2006.01)
A61K 38/26 (2006.01) *A61P 3/00* (2006.01)
C07K 14/605 (2006.01) *A61P 1/00* (2006.01)

(21) International Application Number:

PCT/US2016/037818

(22) International Filing Date:

16 June 2016 (16.06.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/182,847 22 June 2015 (22.06.2015) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US];
Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **CHEN, Yanyun**; c/o Eli Lilly and Company,
P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **MEZO, Adam Robert**; c/o Eli Lilly and Company, P.O.
Box 6288, Indianapolis, Indiana 46206-6288 (US). **QU, Hongchang**; c/o Eli Lilly and Company, P.O. Box 6288,
Indianapolis, Indiana 46206-6288 (US). **VALENZUELA, Francisco Alcides**; c/o Eli Lilly and Company, P. O. Box
6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agents: **GREGORY, Jennifer K.** et al.; Eli Lilly And
Company, P.O. Box 6288, Indianapolis, Indiana 46206-
6288 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) Title: GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS

(57) Abstract: The present invention provides glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH). P-20637



WO 2016/209707 A1